Simplification and Implementation of Awake Fibreoptic Orotracheal Intubation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital, Fudan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- American Society of Anesthesiologists' physical status I-II patients
- Aged 18-75 years
- Mallampati Grade I-II
- Body Mass Index 18.5-28 kg·m-2
Exclusion Criteria:
- Allergic to the drugs involved in the study
- Neck mass or infection
- Drug or alcohol abuse
- Pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The average total time of Awake Fiberoptic Orotracheal Intubation (AFOI)
Time Frame: End of the AFOI
|
The time from the midazolam injection to positive end tidal CO2 acquired (Minutes)
|
End of the AFOI
|
|
The rate of one-time intubation success.
Time Frame: End of the AFOI
|
All steps are successful once (Percentage)
|
End of the AFOI
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systolic blood pressure, SBP (mmHg)
Time Frame: During the AFOI
|
SBP is used to assess hemodynamic fluctuations
|
During the AFOI
|
|
Diastolic blood pressure, DBP (mmHg)
Time Frame: During the AFOI
|
DBP is used to assess hemodynamic fluctuations
|
During the AFOI
|
|
Heart rate, HR (bpm)
Time Frame: During the AFOI
|
HR is used to assess hemodynamic fluctuations
|
During the AFOI
|
|
Rate of amnesia of the intubation
Time Frame: On the first postoperative day
|
It is used to assess anterograde amnesia of midazolam
|
On the first postoperative day
|
|
Ramsay sedation scale
Time Frame: During the AFOI
|
1= anxious or restless or both, 2 = cooperative, orientated and tranquil, 3 = responding to commands, 4 = brisk response to stimulus, 5 = sluggish response to stimulus, 6= No response to stimulus
|
During the AFOI
|
|
Patients' satisfaction
Time Frame: On the first postoperative day
|
1 = excellent, 2 = good, 3 = fair, 4 = poor
|
On the first postoperative day
|
|
Unexpected coughing
Time Frame: During the AFOI
|
Unexpected coughing was evaluated with 4 score (1=none, 2< 3 times unexpected slight coughing comparable to 'clearing ones' throat', 3≥2 times, mild unexpected coughing lasting less than a minute, 4=persistent unexpected coughing)
|
During the AFOI
|
|
Relative complications
Time Frame: End of the surgery and the first postoperative day
|
Such as arrhythmias, bleeding or sore throat
|
End of the surgery and the first postoperative day
|
|
Vocal cord movement
Time Frame: During the AFOI
|
1 = open, 2 = moving, 3 = closing, 4 = closed
|
During the AFOI
|
|
Hypoxic episode
Time Frame: During the AFOI
|
SpO2<90%
|
During the AFOI
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B2017-112R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.